We are now on the verge of viewing effector molecules and other regulatory sites as therapeutic targets for the amelioration of human and animal disease. The recognition, for example, that mutant proteins are frequently misrouted molecules, rather than functionally defective ones, changes our approach to "inborn errors of metabolism" and offers new approaches for pharmacological discovery, based on rescue of receptors, ion channels and enzymes with pharmacoperones. Ion channels, regulators of G-protein signaling and enzymes engaged in regulation, now present opportunities for drug development.

The state of our art also benefits by the availability of superior tools that allow measurement of interactions and afford unprecedented insight into the biomolecular interactions that present novel approaches to drug design.

Molecular and functional diversity of the TRPC family of ion channels. TRPC channels and their role in ROCE/SOCE

Functional Rescue of Misfolded Receptor Mutants
Obesity-related mutations of leptin and melanocortin receptors
cAMP- and cGMP-dependent control of lipolysis and lipid mobilization in humans: putative targets for fat cell management
Central Neuropeptide Receptors Involved in Water Balance: Application to Apelin
Targeting regulators of G protein signaling (RGS proteins) to enhance agonist specificity
Dimeric GPCRs: what did we learn from the metabotropic glutamate receptors?
Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists
Mutations in G proteins and G protein-coupled receptors in human endocrine diseases
A molecular dissection of the glycoprotein hormone receptors
Receptor Tyrosine Kinases as Targets for Cancer Therapy Development
Targets for pituitary tumor therapy
The endogenous cannabinoid system in the control of food intake and energy balance.